CD133+CD24+ Kidney Stem Cells for Renal Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for renal damage, such as dialysis and transplant, are costly and inefficient, highlighting the need for effective kidney stem cells capable of regenerating kidney tissue.
Innovation Solution
Identification and isolation of kidney stem cells co-expressing CD133 and CD24 markers, which demonstrate pluripotency and regenerative capacity, allowing for the derivation of tubular, osteogenic, adipogenic, and neurogenic cell types, and successful implantation in damaged kidneys.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dialysis and transplant treatments are used for renal damage, then patient survival is maintained, but treatment costs are extremely high and treatment efficiency is low
Solution Approach 1:
The patent enables the kidney to repair itself by introducing stem cells that home to damaged areas and differentiate into functional renal cells, replacing the need for external dialysis or transplant interventions. The stem cells autonomously navigate to injury sites and execute repair functions without continuous external support.
Solution Approach 2:
The patent prepares stem cells in advance with specific surface markers (CD133 and CD24) that enable their identification, isolation, and pre-characterization before transplantation. This preliminary preparation ensures the cells are ready for immediate therapeutic deployment and can be quality-controlled before administration.
2Reliability
If traditional kidney stem cell therapy is pursued, then tissue regeneration is needed, but suitable stem cell populations have not been identified
Solution Approach 1:
The patent uses surface marker expression (CD133 and CD24) as identifiable characteristics to distinguish kidney stem cells from other renal cells. These markers serve as biological 'colors' or signatures that enable detection, isolation, and verification of the correct cell population through flow cytometry and immunostaining techniques.
Solution Approach 2:
The patent segments the heterogeneous kidney cell population into distinct subsets based on surface marker expression patterns. By focusing on the specific CD133+CD24+ subset, the patent isolates the therapeutically relevant stem cell population from other renal cells, enabling targeted therapy with purified cell populations.
3Adaptability or versatility
If stem cells are isolated and characterized, then regenerative capacity can be utilized, but the specific cell population and markers must be identified
Solution Approach 1:
The patent identifies stem cells with multiple functional capabilities: self-renewal, differentiation into various renal cell types, homing to damaged tissues, and secretion of regenerative factors. The CD133+CD24+ cell population exhibits all these functions, making it a universal therapeutic agent for various kidney pathologies.
Solution Approach 2:
The patent uses surface markers CD133 and CD24 as intermediary identifiers that facilitate the isolation and characterization of stem cells. These markers serve as mediators between the complex cellular machinery and the researcher's ability to identify, isolate, and verify the correct cell population through standardized immunological techniques.
Data Source
Figure 1a~1e
Figure 2a~2e
Figure 3
AI summary
A novel population of kidney-derived cells is described that exhibits surface co- expression of CD133 and CD24 markers; said cells possess stem cell capacity and are capable of undergoing tubulogenic, adipogenic, osteogenic and neurogenic differentiation.